Key Points
- Insider sale: Barry Ticho sold 5,545 Stoke Therapeutics shares for approximately $170,065 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 21.61% to 20,110 shares.
- Financial performance: Stoke reported quarterly revenue of $9.32 million but posted an adjusted loss of $0.93 per share, missing analysts’ $0.80-loss estimate. Analysts expect a full-year loss of approximately $3.52 per share.
- Analyst outlook: The stock has a “Moderate Buy” consensus rating from analysts, with an average price target of $44.25 versus its recent price near $30, though one firm maintains a sell rating.
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 5,545 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $30.67, for a total transaction of $170,065.15. Following the completion of the transaction, the insider directly owned 20,110 shares in the company, valued at $616,773.70. The trade was a 21.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Barry Ticho also recently made the following trade(s):
- On Tuesday, August 18th, Barry Ticho sold 4,767 shares of Stoke Therapeutics stock. The shares were sold at an average price of $32.03, for a total transaction of $152,687.01.
- On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04.
Stoke Therapeutics Stock Performance
NASDAQ STOK opened at $29.99 on Friday. Stoke Therapeutics, Inc. has a 52-week low of $18.80 and a 52-week high of $40.22. The company has a fifty day moving average of $31.22 and a 200-day moving average of $32.22. The company has a market capitalization of $1.94 billion, a P/E ratio of -8.98 and a beta of 1.23.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The firm had revenue of $9.32 million during the quarter, compared to the consensus estimate of $4.89 million. As a group, analysts forecast that Stoke Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the company. Wedbush increased their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the company an "outperform" rating in a research report on Tuesday, August 4th. Canaccord Genuity Group dropped their target price on Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating for the company in a research report on Tuesday, August 4th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. The Goldman Sachs Group initiated coverage on Stoke Therapeutics in a research note on Monday, July 13th. They issued a "buy" rating and a $44.00 target price for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Stoke Therapeutics in a research report on Friday, August 21st. They set an "overweight" rating and a $40.00 price target on the stock. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $44.25.
Read Our Latest Stock Analysis on Stoke Therapeutics
Institutional Trading of Stoke Therapeutics
Several hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its stake in shares of Stoke Therapeutics by 1.2% during the fourth quarter. AQR Capital Management LLC now owns 29,467 shares of the company's stock valued at $935,000 after buying an additional 354 shares during the last quarter. Versant Capital Management Inc increased its holdings in shares of Stoke Therapeutics by 22.6% in the second quarter. Versant Capital Management Inc now owns 1,951 shares of the company's stock worth $64,000 after buying an additional 359 shares during the period. Strs Ohio increased its holdings in shares of Stoke Therapeutics by 9.4% in the fourth quarter. Strs Ohio now owns 7,000 shares of the company's stock worth $222,000 after buying an additional 600 shares during the period. First Trust Advisors LP lifted its stake in shares of Stoke Therapeutics by 0.5% in the 1st quarter. First Trust Advisors LP now owns 163,459 shares of the company's stock valued at $5,322,000 after acquiring an additional 780 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in shares of Stoke Therapeutics in the 4th quarter valued at about $26,000.
Stoke Therapeutics Company Profile
(
Get Free Report)
Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.
The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
